Boehringer Ingelheim's novel antibody shows potential to transform treatment of rare form of psoriasis
Published in The New England Journal of Medicine, new data show single dose BI 655130* rapidly cleared symptoms of a rare and potentially life-threatening form of pustular psoriasis1

BI 655130 is an investigational, potential first-in-class treatment targeting interleukin-36 receptor (IL-36R)

BI 655130 is being studied in generalised pustular psoriasis as the first of several potential indications, including inflammatory bowel diseases

News Agencies Feed